Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557830 · ClinicalTrials.gov registry record · Phase 2
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Accelerated Community Oncology Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00557830 is a Phase 2 study that was terminated before completion, run by Accelerated Community Oncology Research Network. The registered enrollment target is 12 participants.
The verdict
NCT00557830, a Phase 2 study, was terminated before completion, sponsored by Accelerated Community Oncology Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC. The secondary objectives are to evaluate the effects of the dose-escalation regimen on the quality of life (QoL) of patients with metastatic RCC and to characterize the safety and tolerability profile of a dose-escalation regimen of sorafenib in patients with metastatic RCC.
Interventions
- DRUG Sorafenib Escalated Dose
- DRUG Sorafenib Standard Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00557830
The ClinicalTrials.gov registry entry for NCT00557830 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib Escalated Dose is the first listed.
NCT00557830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00557830 about?
NCT00557830 is a clinical study titled "Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma". The primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC. The secondary objectives are to evaluate the effects of the dose-escalation reg...
What is the current status of trial NCT00557830?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2008-01. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00557830?
The interventions under investigation include: Sorafenib Escalated Dose (DRUG), Sorafenib Standard Dose (DRUG).
Who is sponsoring clinical trial NCT00557830?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.